NASDAQ:DOCS Doximity (DOCS) Stock Price, News & Analysis $51.06 -0.20 (-0.39%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$51.10 +0.04 (+0.09%) As of 05/23/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Doximity Stock (NASDAQ:DOCS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Doximity alerts:Sign Up Key Stats Today's Range$50.00▼$51.2950-Day Range$50.54▼$66.3952-Week Range$25.00▼$85.21Volume1.43 million shsAverage Volume2.09 million shsMarket Capitalization$9.53 billionP/E Ratio51.06Dividend YieldN/APrice Target$61.22Consensus RatingModerate Buy Company OverviewDoximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More… Doximity Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreDOCS MarketRank™: Doximity scored higher than 61% of companies evaluated by MarketBeat, and ranked 385th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingDoximity has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 8 buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageDoximity has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Doximity's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth8.08% Earnings GrowthEarnings for Doximity are expected to grow by 8.08% in the coming year, from $0.99 to $1.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 51.06, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 51.06, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.72.Price to Earnings Growth RatioDoximity has a PEG Ratio of 4.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 9.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DOCS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for DOCS. News and Social Media2.5 / 5News Sentiment0.42 News SentimentDoximity has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Doximity this week, compared to 11 articles on an average week.Search Interest22 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 120% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Doximity to their MarketBeat watchlist in the last 30 days. This is a decrease of -15% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,689,210.00 in company stock.Percentage Held by Insiders37.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.19% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Doximity's insider trading history. Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address DOCS Stock News HeadlinesDoximity, Inc. (NASDAQ:DOCS) Director Sells $113,860.00 in StockMay 3, 2025 | insidertrades.comJim Cramer on Doximity (DOCS): “I Cannot Get Behind That”May 22 at 11:29 PM | insidermonkey.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.May 24, 2025 | Timothy Sykes (Ad)Robert W. Baird Cuts Doximity (NASDAQ:DOCS) Price Target to $65.00May 22 at 2:12 AM | americanbankingnews.comDoximity (NASDAQ:DOCS) Shares Down 3.8% on Analyst DowngradeMay 22 at 1:33 AM | americanbankingnews.comDoximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing InvestigationMay 21 at 8:27 PM | globenewswire.comDoximity to Present at the William Blair 45th Annual Growth Stock ConferenceMay 21 at 4:19 PM | businesswire.comDoximity: A Closer Look at Its Investment PotentialMay 20, 2025 | fool.comSee More Headlines DOCS Stock Analysis - Frequently Asked Questions How have DOCS shares performed this year? Doximity's stock was trading at $53.39 at the start of the year. Since then, DOCS stock has decreased by 4.4% and is now trading at $51.0610. View the best growth stocks for 2025 here. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) released its quarterly earnings data on Thursday, May, 15th. The company reported $0.38 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.11. The company's quarterly revenue was up 17.1% on a year-over-year basis. When did Doximity IPO? Doximity (DOCS) raised $501 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 23,300,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities acted as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Top institutional investors of Doximity include Vanguard Group Inc. (6.53%), Baillie Gifford & Co. (2.21%), Invesco Ltd. (1.05%) and UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC (1.05%). Insiders that own company stock include Anna Bryson, Craig Overpeck, Kira Scherer Wampler, Watkin Phoebe L Yang and Timothy S Cabral. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Doximity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Doximity investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), CrowdStrike (CRWD), PayPal (PYPL) and Invesco QQQ (QQQ). Company Calendar Last Earnings5/15/2025Today5/24/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Custom computer programming services Sub-IndustryComputer Software Current SymbolNASDAQ:DOCS CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees890Year FoundedN/APrice Target and Rating Average Stock Price Target$61.22 High Stock Price Target$90.00 Low Stock Price Target$45.00 Potential Upside/Downside+19.9%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$1.11 Trailing P/E Ratio51.06 Forward P/E Ratio51.58 P/E Growth4.1Net Income$147.58 million Net Margins36.60% Pretax Margin46.01% Return on Equity21.75% Return on Assets18.64% Debt Debt-to-Equity RatioN/A Current Ratio8.74 Quick Ratio8.74 Sales & Book Value Annual Sales$570.40 million Price / Sales16.71 Cash Flow$0.63 per share Price / Cash Flow81.32 Book Value$5.52 per share Price / Book9.25Miscellaneous Outstanding Shares186,692,000Free Float116,869,000Market Cap$9.53 billion OptionableNot Optionable Beta1.41 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:DOCS) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Doximity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.